Corporation
Janssen Inc.
- Meetings this Parliament
- 13
- With MPs
- 3
- Since Nov 2021
- 44
- Active registrations
- 1
Most recent reported meeting: Aug 21, 2026.
Lobbying by Janssen Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Feb 12, 2026
Filed by Laetitia Decroix Guilloux, President
Lobbyists
- Alaine Grand · Vice President, Market Access & Strategic Customers
- Donald Elrick · Head of Regulatory Affairs and Commercial Quality
- Laetitia Decroix Guilloux · President
- Monica Da Re · Senior Manager, Government Affairs & Policy
Institutions they may lobby: Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (17)Hide details
- Canadian Drug Agency: the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives, including patient access and reimbursement framework.
- Communications regarding Canada’s mental health strategy, implementation and access to services for Canadians.
- Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
- Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.
- Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D.
- Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program.
- Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration).
- Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
- Incentives and programs to attract and support manufacturing activities in Canada
- Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
- Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
- COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic.
- Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
- Communications regarding the maintenance of domestic supply of essential drug products.
- Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
- Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
- An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
Registration 962820-14483-49. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Berkeley Vincent (25), Laetitia Decroix Guilloux (8), Jorge Bartolome (7), Alaine Grand (4).
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Justine Frame · Senior Policy Advisor, Health Canada (HC)
Communications regarding the maintenance of domestic supply of essential drug products.
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Health Emergency Readiness Canada, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector. Read more
Incentives and programs to attract and support manufacturing activities in Canada
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Marjorie Michel · Minister of Health, Health Canada (HC)
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. Read more
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. Read more
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. Read more
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. Read more
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs, Privy Council Office (PCO)
- Karim Bardeesy · Parliamentary Secretary to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Marjorie Michel · Minister, Health Canada (HC)
- Nasser Haidar · Senior Policy Advisor, Privy Council Office (PCO)
and 7 moreShow fewer
- Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Office of the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Justine Frame · Policy Advisor, Minister’s Office, Health Canada (HC)
- Sandenga Yeba · Deputy Chief of Staff and Director of Policy to the Minister, Health Canada (HC)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Canadian Drug Agency: the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives, including patient access and reimbursement framework. Read more
Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
Incentives and programs to attract and support manufacturing activities in Canada
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
-
Reported by Laetitia Decroix Guilloux · In-house (corporation)
- Justine Frame · Policy Advisor, Minister’s Office, Health Canada (HC)
Communications regarding Canada’s mental health strategy, implementation and access to services for Canadians.
-
Reported by Alaine Grand · In-house (corporation)
- Gary Xie · Senior Policy Advisor to the Secretary of State, International Development, Global Affairs Canada (GAC)
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector. Read more
Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
-
Reported by Alaine Grand · In-house (corporation)
- Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
- Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations. Read more
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
-
Reported by Alaine Grand · In-house (corporation)
- Scott Reid · Member of Parliament
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector. Read more
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
-
Reported by Alaine Grand · In-house (corporation)
- Iris Petten · Senator, Senate of Canada
- Arianna Knoefel · Director of Parliamentary Affairs, Senate of Canada
Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations. Read more
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
-
Reported by Berkeley Vincent · In-house (corporation)
- Ritu Banerjee · Interim Head, Health Canada (HC)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector. Read more
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
-
Reported by Berkeley Vincent · In-house (corporation)
- Chike Agbasi · Director of Operations, Federal Economic Development Agency for Southern Ontario (FedDev)
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. Read more
-
Reported by Berkeley Vincent · In-house (corporation)
- Sarah Hussaini · Director of Policy, Prime Minister's Office (PMO)
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. Read more
-
Reported by Berkeley Vincent · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
-
Reported by Berkeley Vincent · In-house (corporation)
- François-Philippe Champagne · Minister of Innovation, Science and Industry, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Yasir Naqvi · Member of Parliament
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Jennifer Miller · Assistant Secretary to Cabinet, Privy Council Office (PCO)
HealthIndustry
-
Reported by Berkeley Vincent · In-house (corporation)
- Chris Johnstone · Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.